Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

Blood Amyloid-Beta Relationship With Amyloid Plaques and CSF Amyloid-Beta

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03899844

Acronym

SEABIRD

Enrollment

1122

Registered

2019-04-02

Start date

2019-04-09

Completion date

2024-01-31

Last updated

2024-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Dementia, Alzheimer Disease

Brief summary

The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.

Detailed description

Alzheimer's disease is the most common cause of dementia and currently has no disease-modifying treatments or simple, accurate diagnostic tests. Amyloid beta builds up in the brain and forms plaques in people with Alzheimer's disease, and the buildup of this protein is found decades before symptoms of dementia begin. A blood test may be able to quickly and inexpensively screen people for Alzheimer's disease clinical trials and eventually diagnose Alzheimer's disease in the clinic.

Interventions

OTHERBlood collection, PiB PET/MRI, and cognitive testing

Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Inclusion criteria

1\. At least 60 years of age

Exclusion criteria

1. Unable to perform one or more activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment or dependent on others due to cognitive impairment. 2. Body weight of \<100 pounds 3. Active infectious disease (e.g., HIV, hepatitis B, hepatitis C) 4. Bleeding disorder 5. Taking an experimental drug for AD 6. Blood donation in the last two months 7. Blood transfusion in the last three months 8. On hospice

Design outcomes

Primary

Measure	Time frame
Plasma amyloid-beta 42/40 ratio	Baseline
Area under the curve (AUC) of the blood test (plasma amyloid-beta 42/40 ratio) in predicting amyloid PET status	6 months

Secondary

Measure	Time frame
Coefficient of variation for the initial and confirmatory blood amyloid-beta test results	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026